Comparing Lab and Ultrasound Findings in Letrozole Response in PCOS
Compares lab and ultrasound findings in women with PCOS who respond or not to letrozole.
Plain-language title generated from the registry record
Registry title: Laboratory and Ultrasound Findings and Response to Letrozole in PCOS Patients
Key facts
- Where
- Cairo, EgyptSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for women aged 18-40 years with polycystic ovary syndrome (PCOS) who are starting letrozole to trigger ovulation for the first time.
- Age
- 18 to 40 years
- Sex
- Women only
- Disease stage
- PCOS diagnosed by the Rotterdam criteria
- Earlier treatment
- No earlier use of letrozole to induce ovulation
Main reasons for not taking part
- Infertility from other causes, such as blocked tubes or male factor infertility
- Earlier ovary surgery
- Medicines that could affect ovulation
- Uncontrolled diabetes, high prolactin or thyroid problems
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 40 years old?
Source: NCT06861803, who can take part
Where in Egypt
- Al-Hussein University HospitalCairo, EgyptContact: Muhamed Alhagrasy, M.D.No longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Al-Azhar University
- Trial code
- NCT06861803
- Record updated
- 21 March 2025
- Original description
The goal of this observational study is to compare laboratory and ultrasound findings between letrozole-resistant and letrozole-sensitive PCOS patients in Egypt. The study will include women aged 18-40 years diagnosed with PCOS based on the Rotterdam criteria, who are undergoing ovulation induction with letrozole for the first time.Read full original descriptionShow less
Comparison of Laboratory and Ultrasound Findings Between Letrozole-Resistant and Letrozole-Sensitive PCOS Patients in Egypt
The goal of this observational study is to compare laboratory and ultrasound findings between letrozole-resistant and letrozole-sensitive PCOS patients in Egypt. The study will include women aged 18-40 years diagnosed with PCOS based on the Rotterdam criteria, who are undergoing ovulation induction with letrozole for the first time.
The main questions it aims to answer are:
What are the baseline laboratory and ultrasound differences between letrozole-resistant and letrozole-sensitive PCOS patients? What factors can predict letrozole resistance in PCOS patients? Researchers will compare letrozole-resistant and letrozole-sensitive PCOS patients to determine whether specific laboratory markers and ultrasound findings can predict resistance to letrozole.
Participants will:
Undergo baseline clinical, laboratory, and ultrasound assessments before starting letrozole treatment.
Receive letrozole treatment with dose escalation up to 7.5 mg/day over a maximum of three cycles if ovulation is not achieved.
Be monitored through serial transvaginal ultrasounds to assess follicular development.
Have ovulation confirmed via mid-luteal serum progesterone levels. The study aims to improve the understanding of predictors of letrozole resistance to guide personalized ovulation induction strategies in PCOS patients.
Inclusion: Women aged 18-40 years; Diagnosis of PCOS based on Rotterdam criteria; No prior ovulation induction with letrozole; Willing to follow the treatment protocol and attend follow-up visits.
Exclusion: Previous ovarian surgery or use of medications that could influence ovulation; Comorbidities such as uncontrolled diabetes, hyperprolactinemia, or thyroid dysfunction; Infertility due to other causes such as tubal obstruction or male factor infertility.